OSCR
Oscar Health, Inc.
OSCR has the edge over PBYI overall, supported by stronger fundamentals and stronger valuation.
PBYI
Puma Biotechnology, Inc.
PBYI trails on the overall score without a compensating advantage in the available component scores.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
PBYI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Strong |
PBYI's cash flow and balance sheet are currently strong, and its revenue and profitability are stable.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over PBYI in the historical PE scenario, which offers more potential upside but is not a forecast.
PBYI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.4x | $2.49 | -69% |
| Fair | 12x | $5.71 | -29% |
| Current | 18x | $8.08 | — |
| Expensive | 22x | $10.08 | +25% |
Historical ranges are pointers, not guarantees.
PBYI's PE is in its expensive range at 18x.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
PBYI Forward outlook
There aren't enough analyst estimates for PBYI to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
PBYI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.46 | -39% |
| Q2 2026 | $0.52 | -47% |
| Q1 2026 | $0.48 | -38% |
| Q4 2025 | $0.61 | -1.6% |
| Q3 2025 | $0.75 | +60% |
| Q2 2025 | $0.99 | +450% |
| Q1 2025 | $0.78 | +144% |
| Q4 2024 | $0.62 | +38% |
PBYI's earnings per share have fallen from their peak: $0.46 over the past year, against $0.99 in mid-2025.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over PBYI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
PBYI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $55.1M | +1.1% |
| Q2 2026 | $56.5M | +7.8% |
| Q1 2026 | $44.8M | -2.6% |
| Q4 2025 | $75.5M | +28% |
| Q3 2025 | $54.5M | -32% |
| Q2 2025 | $52.4M | +11% |
| Q1 2025 | $46M | +5.1% |
| Q4 2024 | $59.1M | -18% |
PBYI's revenue is growing: $55M last quarter, up 1.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.6% | -8 points |
| Q2 2026 | 13% | +0.8 points |
| Q1 2026 | -8.5% | -17 points |
| Q4 2025 | 23% | +0.1 points |
| Q3 2025 | 18% | -9.8 points |
| Q2 2025 | 13% | +17 points |
| Q1 2025 | 8.7% | +14 points |
| Q4 2024 | 23% | +2.1 points |
PBYI has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over PBYI on cash flow, with more consistent year-over-year improvement.
PBYI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $14.6M | +51% |
| Q2 2026 | $1.6M | -88% |
| Q1 2026 | $15.4M | +334% |
| Q4 2025 | $14.5M | -7.3% |
| Q3 2025 | $9.7M | -12% |
| Q1 2025 | $3.6M | -68% |
| Q4 2024 | $15.6M | +50% |
| Q3 2024 | $11M | +4.1% |
PBYI generated $46M in free cash flow over the past year, up 7.5% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
PBYI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +520K shares |
| 1 year | +4.3% | +2.2M shares |
| 3 years | +11% | +5.3M shares |
| 5 years | +30% | +12.3M shares |
| Available history | +36% | +14.1M shares |
PBYI has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over PBYI on leverage, with a lower net debt burden relative to earnings.
PBYI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -0.9x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.1x | Net Cash |
PBYI has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
PBYI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.6 | Neutral |
| Stochastic | 35.7 | Neutral |
PBYI's weekly RSI is 46 (neutral) and its Stochastic is 36 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over PBYI on valuation relative to its sector.
PBYI PE vs Healthcare Sector
| Metric | PBYI | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 32% below |
| PE % | 70 | 29 | 41 pts above |
PBYI is trading at 18x earnings, a 32% discount to the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over PBYI on trend strength, trading above more of its moving averages.
PBYI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.65 | 16% below |
| 20 week MA | $9.11 | 11% below |
| 50 week MA | $7.65 | 5.6% above |
| 100 week MA | $5.72 | 41% above |
| 200 week MA | $4.69 | 72% above |
PBYI has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 72% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over PBYI on returns for 2026, with the stronger performance.
PBYI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.66 | $11.4 | +32% |
| 2021 | $11.4 | $3.46 | -70% |
| 2022 | $3.46 | $4.12 | +19% |
| 2023 | $4.12 | $4.33 | +5.1% |
| 2024 | $4.33 | $3.08 | -29% |
| 2025 | $3.08 | $6.16 | +100% |
| 2026 YTD | $6.16 | $8.08 | +31% |
PBYI's yearly returns have swung widely, from +100% in 2025 to −70% in 2021. It's up 31% so far in 2026.